Liminatus Pharma: Funding, Investors & Team (Oct 2026)
Liminatus Pharma is a clinical-stage biopharmaceutical company that specializes in developing immune-modulating cancer therapies. Its pipeline includes a humanized anti-CD47 monoclonal antibody (IBA101) targeting advanced solid tumors, a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II trials for gastrointestinal cancers, and a GCC-targeted CAR-T cell therapy. The company also holds exclusive rights to the YN1203 companion diagnostic for checkpoint inhibitor therapies.
Liminatus Pharma has raised $1.9M across 1 funding round on record, the most recent an undisclosed round of $1.9M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Liminatus Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Liminatus Pharma Funding Rounds
Liminatus Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Liminatus Pharma Funding Compared to Other Biotechnology Startups
Liminatus Pharma's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Liminatus Pharma in Biotechnology and Wilmington
Companies Similar to Liminatus Pharma
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Liminatus Pharma Funding FAQs
What does Liminatus Pharma do?
Liminatus Pharma is a clinical-stage biopharmaceutical company that specializes in developing immune-modulating cancer therapies. Its pipeline includes a humanized anti-CD47 monoclonal antibody (IBA101) targeting advanced solid tumors, a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II trials for gastrointestinal cancers, and a GCC-targeted CAR-T cell therapy. The company also holds exclusive rights to the YN1203 companion diagnostic for checkpoint inhibitor therapies.
How much funding has Liminatus Pharma raised?
Liminatus Pharma has raised $1.9M across 1 round on record. The most recent is an undisclosed round of $1.9M announced in Jun 2026.
When did Liminatus Pharma last raise funding?
Liminatus Pharma's most recent funding round on record is an undisclosed round of $1.9M, announced in Jun 2026.
Who founded Liminatus Pharma?
FundedIQ lists Chris Kim (Founder) at Liminatus Pharma.
Where is Liminatus Pharma headquartered?
Liminatus Pharma is based in Wilmington, Delaware, United States.
How many employees does Liminatus Pharma have?
Liminatus Pharma is in the 1-10 employee band.
How does Liminatus Pharma's funding compare to other Biotechnology startups?
Liminatus Pharma's latest round of $1.9M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Liminatus Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Liminatus Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.